Fig. 61From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (Abstract P154). Sixteen patients demonstrated partial response (confirmed and unconfirmed), including 3 PRs in 5 urothelial carcinoma patients, 3 PRs in 9 RCC patients, 2 PRs in 4 gastric cancer patients, 2 PRs in 2 Merkel cell carcinoma patients, 1 PR in 1 colorectal cancer (CRC) patient with microsatellite instability high (MSI-h) status, among 12 CRC patients, 1 PR in 1 pancreatic cancer patient with MSI-h status, between 2 pancreatic cancer patients, 1 PR in 1 penis squamous cell carcinoma patient, 1 PR in 1 duodenal carcinoma patient, 1 PR in 22 ovarian cancer patients, and 1 PR in 7 mesothelioma patientsBack to article page